Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects.
Progenics Pharmaceuticals Inc and Wyeth Pharmaceuticals are developing methylnaltrexone, a micro-receptor opioid antagonist derived from naltrexone by the addition of a methyl group. The intravenous formulation of methylnaltrexone is currently in phase III clinical trials for the potential treatment of postoperative ileus.
Reichle
Florian M
FM
Ludwig-Maximilians-University, Department of Anesthesiology and Intensive Care Medicine, Nussbaumstrasse 20, 80336, Munich, Germany. Florian.Reichle@med.uni-muenchen.de
Conzen
Peter F
PF
D000701:Analgesics, Opioid / Q000009:adverse effects*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D045823:Ileus / Q000188:drug therapy; D009271:Naltrexone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy; D020250:Postoperative Nausea and Vomiting / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors* / Q000502:physiology; D016055:Urinary Retention / Q000139:chemically induced* / Q000517:prevention & control / Q000628:therapy
D000701:Analgesics, Opioid; D000644:Quaternary Ammonium Compounds; D017450:Receptors, Opioid, mu; C032257:methylnaltrexone; D009271:Naltrexone